These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 2861096)

  • 1. Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.
    Takabatake T; Ohta H; Maekawa M; Yamamoto Y; Ishida Y; Hara H; Nakamura S; Ushiogi Y; Kawabata M; Hashimoto N
    Eur J Clin Pharmacol; 1985; 28(3):327-31. PubMed ID: 2861096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers.
    Inotsume N; Nishimura M; Fujiyama S; Sagara K; Sato T; Imai Y; Matsui H; Nakano M
    Eur J Clin Pharmacol; 1989; 36(5):517-20. PubMed ID: 2568929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of TZU-0460, a new H2-receptor antagonist, in patients with impaired renal function.
    Takabatake T; Ohta H; Yamamoto Y; Ishida Y; Hara H; Nakamura S; Ushiogi Y; Satoh S; Hattori N
    Eur J Clin Pharmacol; 1986; 30(6):709-12. PubMed ID: 2876900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Famotidine disposition in children and adolescents with chronic renal insufficiency.
    Maples HD; James LP; Stowe CD; Jones DP; Hak EB; Blumer JL; Vogt B; Wilson JT; Kearns GL; Wells TG;
    J Clin Pharmacol; 2003 Jan; 43(1):7-14. PubMed ID: 12520622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man.
    Lin JH; Chremos AN; Yeh KC; Antonello J; Hessey GA
    Eur J Clin Pharmacol; 1988; 34(1):41-6. PubMed ID: 2896129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide.
    Klotz U; Arvela P; Rosenkranz B
    Eur J Clin Pharmacol; 1985; 28(6):671-5. PubMed ID: 2866097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of famotidine on renal function in patients with renal insufficiency.
    Abraham PA; Opsahl JA; Halstenson CE; Chremos AN; Matzke GR; Keane WF
    Br J Clin Pharmacol; 1987 Sep; 24(3):385-9. PubMed ID: 2889461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of hydrochlorothiazide in relation to renal function.
    Niemeyer C; Hasenfuss G; Wais U; Knauf H; Schäfer-Korting M; Mutschler E
    Eur J Clin Pharmacol; 1983; 24(5):661-5. PubMed ID: 6873147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of famotidine in renal insufficiency.
    Halstenson CE; Abraham PA; Opsahl JA; Chremos AN; Keane WF; Matzke GR
    J Clin Pharmacol; 1987 Oct; 27(10):782-7. PubMed ID: 3429684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of famotidine, a new histamine H2-receptor antagonist, on renal function.
    Ishigami M; Sezai Y; Shimada Y; Maeda T; Yabuki S
    Nihon Jinzo Gakkai Shi; 1989 Jun; 31(6):687-91. PubMed ID: 2571741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefmenoxime pharmacokinetics in patients with renal insufficiency.
    Polk RE; Sica DA; Kerkering TM; Kline BJ; Patterson PM; Baggett JW
    Antimicrob Agents Chemother; 1984 Sep; 26(3):322-7. PubMed ID: 6095752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.
    Boike SC; Pue MA; Freed MI; Audet PR; Fairless A; Ilson BE; Zariffa N; Jorkasky DK
    Clin Pharmacol Ther; 1994 Apr; 55(4):418-26. PubMed ID: 8162668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
    Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
    J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and dynamics of famotidine in patients with renal failure.
    Gladziwa U; Klotz U; Krishna DR; Schmitt H; Glöckner WM; Mann H
    Br J Clin Pharmacol; 1988 Sep; 26(3):315-21. PubMed ID: 2902874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.
    Kneer J; Tam YK; Blouin RA; Frey FJ; Keller E; Stathakis C; Luginbuehl B; Stoeckel K
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1952-7. PubMed ID: 2610506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nizatidine disposition in subjects with normal and impaired renal function.
    Aronoff GR; Bergstrom RF; Bopp RJ; Sloan RS; Callaghan JT
    Clin Pharmacol Ther; 1988 Jun; 43(6):688-95. PubMed ID: 2897890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.
    Lin JH
    Clin Pharmacokinet; 1991 Mar; 20(3):218-36. PubMed ID: 1673880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.
    Paap CM; Nahata MC; Mentser MA; Mahan JD; Puri SK; Hubbard JW
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1879-83. PubMed ID: 1952862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary excretion kinetics of famotidine in rats.
    Lin JH; Los LE; Ulm EH; Duggan DE
    Drug Metab Dispos; 1987; 15(2):212-6. PubMed ID: 2882981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of lomefloxacin in renally compromised patients.
    Blum RA; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2364-8. PubMed ID: 2088191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.